Multiple Sclerosis AAN Video Highlights

Video

Aaron Miller, MD, Hideki Garren, MD, and Kate Dawson, MD, discuss the top findings for teriflunomide, ocrelizumab, and tecfidera plus tysabri from the The 69th American Academy of Neurology Annual Meeting for patients with multiple sclerosis.

Miller, professor of Neurology and medical director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Hospital in New York, discusses the safety profile of teriflunomide for patients with multiple sclerosis.

Garren, group medical director, Genentech & Roche Pharmaceutical, discusses ocrelizumab (Ocrevus) for relapsing, primary progressive multiple sclerosis.

Dawson, VP, US Medical Biogen, discusses early treatment with tecfidera and tysabri for patients with multiple sclerosis.


Related Videos
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
Shauna Applin, ARNP, an expert on HIV
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
© 2024 MJH Life Sciences

All rights reserved.